R3i Editorials

R3i editorials, created by members of the R3i board, focus on addressing the persistent challenges of residual cardiovascular risk. These editorials serve to educate healthcare professionals about emerging insights and therapeutic strategies related to lipid-related risk factors, such as triglyceride-rich lipoproteins and lipoprotein(a).

Latest Editorial

May 2026
A wake-up call to the challenge of cardiovascular disease
Prof. Peter Libby, Prof. Michel Hermans, Prof. Pierre Amarenco, Prof. Lale Tokgözoglu 

The latest data from the European Society of Cardiology (ESC) Atlas of Cardiology (1) reaffirm cardiovascular disease as one of the major health challenges in the 21st century. In Europe, cardiovascular disease is responsible for more than 3 million deaths annually; globally, more than 20 million people – about one in three – die due to cardiovascular disease (2). Increasingly, middle income countries are shouldering more of this burden, underlining inequalities in cardiovascular risk, outcomes, and access to treatment.

While clinical guidelines provide evidence-based recommendations, implementation remains an issue. Latest findings from the SANTORINI study (3,4), a prospective observational study in 14 European countries involving patients with high and very high cardiovascular risk, support this. Although the study showed improvement in the use of lipid lowering therapy and low-density lipoprotein (LDL) cholesterol levels over one year follow-up, this was largely driven by an increase in the use of monotherapy. Reflecting this, attainment of guideline-recommended LDL cholesterol goals was suboptimal. Only about one-third of the SANTORINI cohort met the 2019 ESC/European Atherosclerosis Society LDL cholesterol goals; two-thirds of patients did not receive intensification of lipid-lowering therapy during follow-up, despite failing to attain LDL cholesterol goal on monotherapy (4,5).  

Long-term adherence to lipid lowering therapy also remains a concern, as illustrated by a recent Canadian study (6). Analysis of data from more than 11,000 patients with coronary artery disease followed over an 18-year period showed improvement in the proportion with good short-term (up to one year) adherence to lipid lowering therapy. However, there was no significant improvement in long-term adherence, with detrimental effect on cardiovascular outcome. 

Inadequate guideline implementation also affects the uptake of diagnostic testing. For example, although both European and U.S. guidelines recommend lipoprotein(a) [Lp(a)] testing at least once for all adults (5,7), uptake remains low even in high-risk patients with established cardiovascular disease (8). This is despite evidence that about one in four individuals with atherosclerotic cardiovascular disease (ASCVD) have an elevated Lp(a) >50 mg/dL (>125 nmol/L) (9). Among these high-risk patients with peripheral artery disease, for whom elevated Lp(a) is associated with worsening prognosis (10), U.S. data show that fewer than 1.5% of patients underwent Lp(a) testing (11). Increased awareness of Lp(a) and improved adherence to guideline-recommended testing are needed to address this substantial implementation gap between guideline recommendations and real-world clinical practice. 

 

Central to the global challenge of cardiovascular disease are avoidable inequalities in access to best care. Advances in treatments with proven efficacy in addressing residual cardiovascular risk, are rarely available beyond high-income countries. This is highly relevant given that the major modifiable risk factors, notably hypertension, dyslipidemia, obesity and diabetes, are prevalent in lower to middle income regions. For example, dyslipidemia is a major contributor to the burden of ASCVD in the Middle East and North Africa (MENA) region (12). However, despite recommendations for more intensive lipid lowering across cardiovascular risk categories (13), access to highly efficacious newer therapies including PCSK9 inhibitors is restricted due to high medication costs, strict insurance reimbursement policies, and necessary out-of-pocket expenses. 

This update of the ESC cardiovascular disease statistics, together with global data, provide a wake-up call for the escalating burden of cardiovascular disease, especially in regions least equipped to cope. Pragmatic and effective public health strategies are urgently needed.

 

References

      1. Timmis A, Petersen SE, Van Belle E, et al. European Society of Cardiology: cardiovascular disease statistics 2025. Eur Heart J 2026; doi:10.1093/eurheartj/ehag345.
      2. Global Burden of Disease study. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. JACC 2025; doi: 10.1016/j.jacc.2025.08.015
      3. Connolly DL, Vilaro M, Komen J, et al. Age-stratified analysis of real-world lipid-lowering therapy use and LDL-C goal attainment at 1-year follow-up: insights from the European SANTORINI study. Eur Heart J 2025;46: doi: 10.1093/eurheartj/ehaf784.4056.
      4. Connolly D, Fuat A, McCormack T, et al. Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up. BMJ Open 2026;16:e114031.
      5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88.
      6. Vikulova DN, Pinheiro-Muller D, Pimstone SN, Brunham LR. Temporal trends in lipid- lowering therapy use and adherence in patients with premature coronary artery disease. J Am Heart Assoc 2026; 5:e046415. doi: 10.1161/JAHA.125.046415.
      7. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2026:S0735-1097(25)10254-4.
      8. Chen G, Farris MS, Cowling T, et al. Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study. Clin Cardiol 2021; 44: 1613-20.
      9. Nissen SE, Wolski K, Cho L, et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart 2022;9:e002060.
      10. Bhatia HS, Dalal S, Ross E. Peripheral arterial disease associated with elevated lipoprotein(a): a review of the evidence and treatment approaches. Curr Opin Lipidol 2025;36:238–50.
      11. Naguiba M, Fascetti AJ, Ross EG, et al. Marked underutilization of lipoprotein(a) testing in peripheral artery disease: a national analysis of 8.3 million patients. Am J Prevent Cardiol 2026; doi: 10.1016/j.ajpc.2026.101628.
      12. Taheri E, Esmaeili S, Hamidizadeh S, et al. Long-term trends in dyslipidemia prevalence, awareness, treatment, and control in the Middle East and North Africa: a meta-analysis of 116 representative surveys. Atherosclerosis 2026; doi: 10.1016/j.atherosclerosis.2026.120725
      13. Alsayed N, Almahmeed W, Alnouri F, et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis 2022;343: 28-50.

       

      Key words: Cardiovascular disease statistics; LDL cholesterol goal attainment; lipoprotein(a) testing uptake; treatment inequity